Novaliq GmbH benoemt Friedrich von Bohlen tot voorzitter raad van toezicht, Gerald Cagle lid van raad
HEIDELBERG, Duitsland–(BUSINESS WIRE)– Novaliq GmbH, een farmaceut met een vernieuwend toedieningsplatform dat moeilijk oplosbare medicijnen omvormt tot effectieve oogheelkundige therapieën, heeft vandaag bekendgemaakt dat Friedrich von Bohlen is benoemd tot voorzitter van de raad van toezicht. Daarnaast kondigt het bedrijf aan dat Jerry Cagle is toegetreden als lid van de toezichthoudende raad.
Von Bohlen is sinds 1997 actief binnen de levenswetenschappelijke sector en heeft meer dan twintig jaar ervaring als ondernemer. Hij was in 2005 medeoprichter van dievini Hopp BioTech holding GmbH & Co KG., waar hij de positie van algemeen directeur bekleedt. Daarnaast is hij voorzitter van de raden van toezicht van enkele bedrijven uit de dievini-portefeuille.
Novaliq GmbH Appoints Friedrich von Bohlen, PhD, as Chairman and Gerald Cagle, PhD, as New Member of Novaliq’s Supervisory Board
HEIDELBERG, Germany–(BUSINESS WIRE)– Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that Friedrich von Bohlen, PhD, has been appointed Chairman of the company’s Supervisory Board and that Jerry Cagle, PhD, has joined the Board as Member.
Dr. von Bohlen has been active in the Life Sciences since 1997 and brings 20 years of entrepreneurial experience to his position. In 2005, Dr. von Bohlen co-founded dievini Hopp BioTech holding GmbH & Co KG. where he holds the position of Managing Director. Furthermore, he serves as chairman or board member of several supervisory boards that are part of the dievini portfolio. Dr. von Bohlen began his professional career in 1992 serving as a project manager in research & development at Fresenius AG. He then served as assistant to the chairman of the supervisory board of FAG Kugelfischer KGaA, and thereafter as CEO of Wasag Chemie AG. In 1997 he co-founded Lion Bioscience AG where he served as CEO until 2004 when he was named Chairman of the Board. Dr. von Bohlen holds a Diploma in Biochemistry from the University of Zurich and a PhD in Neurobiology from the Swiss Federal Institute of Technology.
Dr. Cagle began his career as an academic, serving as a faculty member of The Ohio State University in Columbus. Thereafter, and for more than three decades, he worked as a member of Alcon’s research and development team. In 1996, Dr. Cagle was named Senior Vice President of Alcon R&D and Chief Scientific Officer, a position he held until mid-2008. As head of Alcon R&D, he led the global activities of some 1,300 scientists stationed around the world. The productivity of the R&D organization, and the new products introduced during his tenure, has been recognized as a primary contributor to Alcon’s significant growth. Following his departure from Alcon, he worked on the management of Alzheimer’s disease. He serves on the Board of Aerie Pharmaceuticals, Clearside Biomedical, AB2, and GrayBug. Dr. Cagle received his B.S. degree from Wayland College in Plainview, Texas, and earned both his MS and PhD degrees from the University of North Texas in Denton, Texas.
“We are pleased to have Friedrich join Novaliq as the chairman of our supervisory board. His 20 years of entrepreneurial experience is of great importance for the further prosperity of the company and especially in building a successful specialty pharma company focusing on ophthalmology,” said Mr. Günther, Novaliq’s CEO and Managing Director.
“We are delighted to have Jerry join our supervisory board. His long-term experience and vast ophthalmic knowledge is a great win for Novaliq and important for future company growth,” said Dr. Schlüter, Novaliq’s CFO and Managing Director.
“Jerry’s broad business and R&D background in this industry is an important contribution and will be crucial for Novaliq with regard to the evaluation and development of highly effective ocular therapeutics,” said Dr. von Bohlen, Chairman of Novaliq’s Supervisory Board.
“I’m excited about my new assignment as supervisory board member and look forward to being a part of Novaliq’s further development and growth. With the recent European market launch of EvoTears®, Novaliq has made a significant contribution and step forward in the treatment of dry eye disease,” said Dr. Cagle.
About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical and drug delivery company with the mission to transform poorly soluble drugs into effective ocular therapeutics for both front and back of the eye. Novaliq’s proprietary technology enhances the topical bio availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq’s most advanced product is EvoTears® with CE-marking based on Novaliq’s proprietary EyeSol® Technology. More on www.novaliq.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151208005247/en/
Contacts
Europe
Novaliq GmbH
Bernhard Günther, + 49 6221 502 5911
Managing Director, CEO
info@novaliq.de
or
USA
Scot ia Vision Consultants
Michael O’Rourke, + 1 813-323-1438
scotiavc@gmail.com
or
Novaliq GmbH
Oliver Schlüter, PhD, + 49 6221 502 59155
Managing Director, CFO
info@novaliq.de